United Therapeutics Corporation (UTHR) : The consensus on United Therapeutics Corporation (UTHR) based on 9 analyst recommendation on the company stock is 2.56, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
United Therapeutics Corporation (UTHR) : 8 Wall Street analysts covering United Therapeutics Corporation (UTHR) believe that the average level the stock could reach for the short term is $134.25. The maximum price target given is $229 and the minimum target for short term is around $95, hence the standard deviation is calculated at $40.2.
Company shares have received an average consensus rating of Hold for the current week United Therapeutics Corporation (NASDAQ:UTHR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $123.25 and $122.89 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $124.84. The buying momentum continued till the end and the stock did not give up its gains. It closed at $124.33, notching a gain of 1.02% for the day. The total traded volume was 311,237 . The stock had closed at $123.08 on the previous day.
In a related news,The director officer (Chairman & CEO) of United Therapeutics Corp, Rothblatt Martine A sold 1,249 shares at $125.94 on August 4, 2016. The Insider selling transaction had a total value worth of $157,299. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.